文献速递药物相互作用

基于PBPK模型预测奥普佐米对CYP3A的DDI潜力

Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
PubMed 文献 · Br J Clin Pharmacol · 2018-12-25

奥普佐米是口服第二代不可逆蛋白酶体抑制剂,可抑制CYP mRNA。研究采用人肝细胞数据和PBPK模型预测其CYP3A4介导的DDI潜力,并在晚期恶性肿瘤患者中以咪达唑仑为底物开展临床DDI研究。PBPK模型前瞻性预测奥普佐米300 mg不会导致CYP3A4底物暴露发生临床相关变化(≤30%),临床研究结果证实了该预测。

要点

  • PBPK模型预测奥普佐米300 mg对CYP3A4底物暴露影响≤30%,临床DDI研究证实。
  • 奥普佐米抑制人CYP3A4底物代谢的潜力较低。
  • 培养人肝细胞比人肝微粒体更可靠地预测该类化合物的DDI。

核心结论

  • 奥普佐米在人体内抑制CYP3A4底物代谢的潜力较低。
  • 培养人肝细胞是研究该类化合物DDI比人肝微粒体更可靠的系统。
  • 在临床DDI研究前开发PBPK模型有助于支持奥普佐米的临床开发。

研究设计与样本

  • 采用人肝细胞数据和PBPK模型预测奥普佐米CYP3A4介导的DDI潜力。
  • 随后以咪达唑仑为底物在晚期恶性肿瘤患者中开展临床DDI研究,共入组21例患者,其中18例为晚期实体瘤。

主要发现

  • PBPK模型前瞻性预测奥普佐米300 mg不会导致CYP3A4底物暴露发生临床相关变化(≤30%)。
  • 临床DDI研究结果证实了PBPK模型的预测。
  • 没有患者因治疗相关不良事件而停用奥普佐米。

关键数值与推荐

  • PBPK模型预测奥普佐米300 mg对CYP3A4底物暴露的变化≤30%,临床DDI研究证实该预测。

临床怎么用

  • 基于PBPK模型和临床DDI研究结果,奥普佐米与CYP3A4底物联用时预计无需进行剂量调整。
  • 在早期临床开发中,可优先使用培养人肝细胞结合PBPK模型预测CYP mRNA抑制类化合物的DDI风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug that demonstrates cytochrome P450 (CYP) mRNA suppression. This unusual property elicits uncertainty regarding the optimal approach for predicting its drug-drug interaction (DDI) risk. The current study aims to understand DDI potential during early clinical development of oprozomib. METHODS: To support early development of oprozomib (e.g. inclusion/exclusion criteria, combination study design), we used human hepatocyte data and physiologically-based pharmacokinetic (PBPK) modelling to predict its CYP3A4-mediated DDI potential. Subsequently, a clinical DDI study using midazolam as the substrate was conducted in patients with advanced malignancies. RESULTS: The clinical DDI study enrolled a total of 21 patients, 18 with advanced solid tumours. No patient discontinued oprozomib due to a treatment-related adverse event. The PBPK model prospectively predicted oprozomib 300 mg would not cause a clinically relevant change in exposure to CYP3A4 substrates (≤30%), which was confirmed by the results of this clinical DDI study. CONCLUSIONS: These results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans. The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds. Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ou Y, Xu Y, Gore L, et al. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. Br J Clin Pharmacol. 2018. PMID: 30428505. doi:10.1111/bcp.13817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。